QRG Capital Management Inc. Sells 22,874 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• QRG Capital Management Inc. has reduced its stake in Thermo Fisher Scientific by 51.1%, selling 22,874 shares during the second quarter, leaving it with 21,933 shares valued at approximately $8.89 million.
• Several other institutional investors, including Brighton Jones LLC and Vest Financial LLC, have increased their stakes in Thermo Fisher Scientific, indicating ongoing interest in the company's stock.
• Wall Street analysts remain mostly positive about Thermo Fisher Scientifc, with a consensus "Moderate Buy" rating and a target price of $585.37.

QRG Capital Management Inc. lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 51.1% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 21,933 shares of the medical research company's stock after selling 22,874 shares during the period. QRG Capital Management Inc.'s holdings in Thermo Fisher Scientific were worth $8,893,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of TMO. Brighton Jones LLC increased its stake in Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after purchasing an additional 988 shares in the last quarter. Revolve Wealth Partners LLC increased its stake in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares in the last quarter. Vest Financial LLC increased its stake in Thermo Fisher Scientific by 73.4% in the first quarter. Vest Financial LLC now owns 3,188 shares of the medical research company's stock valued at $1,586,000 after purchasing an additional 1,349 shares in the last quarter. Signal Advisors Wealth LLC increased its position in shares of Thermo Fisher Scientific by 7.2% during the first quarter. Signal Advisors Wealth LLC now owns 1,297 shares of the medical research company's stock worth $646,000 after acquiring an additional 87 shares in the last quarter. Finally, Eagle Rock Investment Company LLC increased its position in shares of Thermo Fisher Scientific by 0.3% during the first quarter. Eagle Rock Investment Company LLC now owns 7,489 shares of the medical research company's stock worth $3,727,000 after acquiring an additional 26 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on TMO shares. UBS Group increased their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. Robert W. Baird increased their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Evercore ISI lowered their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Weiss Ratings reissued a "hold (c-)" rating on shares of Thermo Fisher Scientific in a research report on Saturday, September 27th. Finally, Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Fifteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $585.37.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock worth $14,182,963 over the last quarter. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $543.88 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97. The firm has a fifty day simple moving average of $482.58 and a 200 day simple moving average of $447.27. The stock has a market capitalization of $205.37 billion, a price-to-earnings ratio of 31.46, a PEG ratio of 2.95 and a beta of 0.77. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter in the prior year, the company posted $5.37 earnings per share. The firm's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.